




























Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Blower, P. J. (2016). The future direction of radiopharmaceutical development. In A History of Radionuclide
Studies in the UK: 50th Anniversary of the British Nuclear Medicine Society. (pp. 141-148). Springer
International Publishing Switzerland. DOI: 10.1007/978-3-319-28624-2_19
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 15. Dec. 2017
141© The Author(s) 2016
R. McCready et al. (eds.), A History of Radionuclide Studies in the UK: 
50th Anniversary of the British Nuclear Medicine Society, 
DOI 10.1007/978-3-319-28624-2_19
 P. J.  Blower  
 Division of Imaging Sciences and Biomedical Engineering , 
 King’s College London, St Thomas’ Hospital ,  4th Floor Lambeth Wing , 
 London  SE1 7EH ,  UK 
 19 The Future Direction of Radiopharmaceutical Development 
 Philip  J.  Blower 
 The fi rst use in humans of  24 Na-sodium chloride by Hamilton and Stone in 1936 [ 1 ] 
began a story in which  131 I-iodide became established for treating thyroid disease 
and radionuclide imaging became routine in hospitals. As important as the fi rst 
commercial gamma camera (1968) [ 2 ] was the  99m Tc generator, an elegantly simple 
device that solved the problem of world-wide distribution of a short half-life radio-
nuclide, fi rst used for medical purposes in 1961 [ 2 ]. A range of  99m Tc-radiotracers 
quickly became available, including complexes of DTPA (renal function, lung ven-
tilation),  meso -DMSA (renal perfusion), bisphosphonates (bone), HIDA (liver) and 
various colloids (predating “nanotechnology” by decades) and macroaggregated 
albumin. They were easily synthesised in hospitals using simple kit vials, fi rmly 
establishing  99m Tc as the staple medical radionuclide. They were largely serendipi-
tous, arising from biological experiments using “off the shelf” chelating ligands 
selected without detailed knowledge of basic technetium chemistry [ 3 ], which was 
almost unstudied at that time. The simple preparation disguised extremely complex 
coordination chemistry. In most cases their structures remain unknown even now, 
and their approval in today’s regulatory climate would have been most unlikely. 
Nevertheless they were extremely successful. 
 In the 1980s and 1990s, pioneered by leaders such as Davison and Deutsch, 
understanding of technetium chemistry grew [ 4 ] producing a new generation of 
tracers with a greater element of chemical design and with well-defi ned structures, 
but still with simple, kit-based labelling. The concept of technetium “cores” 
emerged – well-defi ned, stable complexes adapted to the coordination preferences 
of technetium, that could be functionalised for different purposes. Examples include 
the TcO 3+ core (the basis of tracers such as MAG3 complex for renal function 
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imaging, “pentavalent” DMSA complex for medullary thyroid carcinoma and bone 
disease, HMPAO complex for cerebral perfusion imaging and cell labelling), 
Tc(isonitrile) 6 + (sestamibi for myocardial perfusion imaging), TcO 2 + (with tet-
raamine or diphosphine chelating ligands such as tetrofosmin), Tc(CO) 3 + and 
TcN(dithiocarbamate) 2 . 
 This set the stage for radiotracer design to shift towards targeting specifi c recep-
tors and transporters, by incorporating  99m Tc into peptides and proteins [ 3 ], and the 
term “molecular imaging” became both fashionable and relevant. It remained an 
important aspiration to synthesise  99m Tc-radiopharmaceuticals via simple processes 
that are quick and use mild, aqueous conditions, avoiding the need for purifi cation 
which adds undesirable complexity. However,  99m Tc chemistry is complex, entailing 
both exchange of ligands and reduction of Tc(VII), and success has been limited. 
Radiolabelling procedures for biomolecules still involve multiple manipulations 
and poor specifi c activity. Hydrazinonicotinamide (hynic) and tricarbonyl 
(Tc(CO) 3 + ) complexes come closest to achieving this, but both fall short and neither 
has led to commercial products. Due to a shift in commercial interests towards PET, 
very little effort has been devoted to this problem in the last decade and it remains a 
challenge to achieve “one-step”  99m Tc biomolecule labelling. 
 Although emergence of positron emission tomography (PET) was roughly con-
temporaneous with that of the gamma camera, PET only became a routine clinical 
diagnostic tool in the 1990s, primarily driven by clinical use of the glucose analogue 
 18 F-fl uorodeoxyglucose. The clinical adoption of PET demanded signifi cant invest-
ment in infrastructure, requiring cyclotron installation within 2–4 h travelling dis-
tance of PET scanners. Availability of this costly new infrastructure spawned 
development of a much wider variety of PET tracers to enhance its versatility. Its 
better resolution and quantifi cation made it increasingly attractive even for applica-
tions that do not require organic small molecules, creating roles for metallic 
positron- emitting radionuclides –  68 Ga,  89 Zr and copper isotopes  60/61/62/64 Cu – which, 
like  99m Tc, are easier to use for proteins and peptides than  18 F and  11 C. 
 68 Ga (half-life 68 min) is rapidly emerging as “the new technetium” – a short 
half-life, generator-produced radiometal that is easily introduced into biomolecules. 
It produces a high positron yield and is readily chelated [ 5 ] with good kinetic stabil-
ity. Despite growing clinical use, especially in Europe, the fi rst commercial genera-
tor received marketing authorisation as recently as 2014. Although gallium 
chemistry is simpler than that of technetium (with only one relevant oxidation state 
(III)), the established chelating agents used to couple it to biomolecules require 
heating, low pH and purifi cation steps, and have not been conducive to use in hos-
pitals with limited radiochemistry facilities. A single-step, kit-based labelling pro-
cedure that works at room temperature, moderate pH and very low concentration 
would greatly increase its utility. Fortunately, considerable efforts have focused 
recently on developing new chelators to overcome these problems [ 5 ] and we will 
see their impact soon (Fig.  19.1 ).
 Large biomolecules (e.g., monoclonal antibodies) with slow localisation and 
clearance require longer half-life tracers. The staple long half-life gamma-emitter 
has been  111 In, which can be attached to proteins using bifunctional chelators, usually 
DTPA and DOTA. A longer half-life “PET analogue” has inevitably emerged: 
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zirconium-89, and with desferrioxamine B as an effective bifunctional chelator for 
zirconium,  89 Zr PET has now been used to image the biodistribution and targeting of 
many antibodies (“immunoPET”) in animal models and humans [ 6 ]. Longer-lived 
radionuclides can also usefully be incorporated into living cells to image their migra-
tion  in vivo . Tracking leukocytes in this way using  111 In or  99m Tc has been routine 
since the 1980s. A PET analogue would offer improvements in sensitivity, quantifi -
cation and resolution suitable for new challenges in cell tracking emerging from the 
development of cell-based therapies and discoveries in cellular immunology. Indeed, 
the fi rst  89 Zr cell labelling radiopharmaceuticals have been reported recently [ 7 ] 
(Fig.  19.2 ). Refi nement in their chemistry, widespread preclinical and clinical appli-
cation, and commercial availability may be anticipated in the coming years.
 While  64 Cu has been widely studied in the last 20 years as a medium half-life 
positron emitter for biomolecule labeling, cell tracking and hypoxia imaging, it has 
begun to give way to alternatives. However its potential to study pathophysiological 
changes in copper traffi cking (Fig.  19.3 ) in, for example, Wilson’s disease, Menkes’ 
disease, dementias (notably Alzheimer’s), cancers and nutritional abnormalities [ 8 ] 
is now emerging. Similar possibilities are emerging to study other essential trace 
metals such as zinc (using  63 Zn) and manganese (using  52 Mn). This is a new fi eld in 
which molecular imaging with radionuclides can make a major impact.
 The combination of different imaging modalities that complement each other to 
overcome their individual limitations is a current trend. For example, while PET and 
SPECT have exquisite sensitivity (sub-picomolar concentrations in vivo) and pro-
vide truly “molecular” imaging, their resolution is poor. Magnetic resonance imag-
ing (MRI), on the other hand, offers better anatomical resolution but large amounts 
of contrast agent are required, while optical imaging can be used at cell level [ 9 ] 
(unlike radionuclides and MRI) but is restricted in clinical use by poor tissue pene-
tration. A new generation of scanners combining PET and MRI is now entering 
 Fig. 19.1  PET-CT images of mouse bearing prostate-specifi c membrane antigen ( PSMA ) express-
ing prostate tumour ( left ), PSMA-expressing tumour (previously injected with a blocking dose of 
PSMA ligand) ( centre ), and PSMA-negative tumour ( right ), 1 h after injection of  68 Ga-labelled 
PSMA ligand conjugate of a tris(hydroxypyridinone) chelator ( left ) synthesised by a kit method at 
room temperature and pH 7 (Young J, Mullen GED, Blower PJ, 2015) 
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clinical use, driving new chemistry to produce combined modality contrast agents. 
For example, incorporating radionuclides into superparamagnetic iron oxide 
nanoparticles (SPION) allows combination of PET or SPECT with MRI. While par-
ticulate radiopharmaceuticals have been clinically used since the earliest days of 
nuclear medicine, the recent accumulation of capability in design, synthesis and 
characterisation of nanoparticles greatly enhances potential for multimodality imag-
ing, albeit in specifi c niche areas such as imaging sentinel lymph nodes [ 10 ] 
(Fig.  19.4 ), reticuloendothelial system (liver, spleen, bone marrow), tumours 
(exploiting the enhanced permeability and retention effect), cell labelling and 
liposome- mediated drug and gene delivery.
 In summary, the close cooperation of clinicians, physicists, engineers, biolo-
gists and chemists identifi es capabilities, conceives challenges, discovers solu-
tions and applies them in the clinic. Each discipline produces innovations that in 
turn drive innovations in the others. This is illustrated by the shift in the last 
decades from single photon radionuclide imaging towards PET, and in turn the 
 Fig. 19.2  Cell tracking with PET. PET-CT image of mouse 7 days after intravenous injection of 
5T-33 myeloma cells labelled with  89 Zr tetrakis(oxinate), showing traffi cking to liver, spleen and 




emerging shift from PET/CT towards PET/MRI and combination of these with 
optical imaging [ 9 ], which has led to new PET and combined modality radiophar-
maceuticals. The next decade may see this recapitulated: the development of a 
new generation of gamma/SPECT scanners with resolution rivalling or exceeding 
that of PET will encourage renewed use and development of  99m Tc tracers. The 
recently highlighted global fragility of  99m Tc supply, far from foreshadowing the 
demise of  99m Tc and SPECT, has stimulated renewed international effort to plan 
new reactors and cyclotron-based production, and develop new generator designs 
to cope with lower specifi c activity  99 Mo. This may soon stimulate a reversal in the 
recent decline of  99m Tc chemistry research, producing innovations appropriate to 
the age of molecular imaging. New initiatives to develop a whole body PET scan-
ner will stimulate increased use of short half-life radionuclides in combination 
(e.g.,  82 Rb,  62 Cu,  13 N,  18 O) in a research setting, for metabolic characterisation of 
tissues in unprecedented detail by imaging multiple molecular targets in a single 
subject, again potentially in combination with MRI and MR spectroscopy. The 
arrival of cell-based therapies will bring improvements in use of radiopharmaceu-
ticals for cell tracking, again using a multimodality approach. Conversely, the 
arrival of new, simple chemistry for  68 Ga may drive the installation of more PET 
scanners. 
 On a fi nal optimistic note, there are hopeful signs that the adverse regulatory 
climate in the new millennium, which has held back the clinical and commercial 
translation of the wealth of new molecular imaging chemistry developed in the last 
15 years, is at last becoming more amenable.  
 Fig. 19.3  PET-CT imaging of copper traffi cking. 
Sagittal section (anterior at top of image) of mouse 
brain 30 min after injection of 64Cu-acetate, showing 
delivery to brain via choroid plexus. Left ventricle and 
fourth ventricle are indicated by  arrows (Andreozzi, 
Bagunya-Torres, Blower, 2015) 
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